New 'Four-in-One' antibody takes on Hard-to-Treat blood cancers
NCT ID NCT05944978
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This early-phase study tests a new drug called GNC-035, a special antibody that targets cancer cells in four ways. It is for people with chronic lymphocytic leukemia (CLL) or other blood cancers that have come back or stopped responding to treatment. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Only 3 participants are enrolled so far.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.